A phase 1, multicenter study evaluated the use of PvD in patients with proteasome inhibitor–exposed and lenalidomide-refractory multiple myeloma to examine the maximum tolerated dose with secondary end points of safety, overall response rate, duration of response, and time to response.
The phase 1/2 Alliance study sought to evaluate the safety and preliminary efficacy of the combination of ixazomib/pomalidomide/dexamethasone in patients with double-refractory multiple myeloma compared with the approved combination of pomalidomide/dexamethasone. Here, they report the phase 1 portion of the Alliance study.
Investigators examined the safety and efficacy of the combination of lenalidomide/ixazomib as a maintenance therapy after ASCT in a single-arm phase 2 study. Favorable results of this combination may warrant additional examination in a phase 3 study.
Results of a randomized, phase 2 study to determine the confirmed overall response rate in patients treated with ixazomib, an orally bioavailable proteasome inhibitor, for patients with relapsed multiple myeloma not refractory to bortezomib.
Carfilzomib/Dexamethasone versus Bortezomib/Dexamethasone in Relapsed MM: Subgroup Analysis Based on Cytogenetic Risk Status of the ENDEAVOR Study
The ENDEAVOR study demonstrated that carfilzomib plus dexamethasone showed a significant improvement in median progression-free survival compared with bortezomib plus dexamethasone. This update examines outcomes in patients in high-risk cytogenetic subgroups.
Using a combined analysis of 2 DARA clinical studies, researchers assessed the overall response rates and clinical activity of a 16-mg/kg infusion for the treatment of relapsed and refractory multiple myeloma in heavily treated patients.
Elotuzumab plus Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory MM: ELOQUENT-2 Trial Update
In a phase 3 study, researchers assessed the safety and efficacy of elotuzumab plus lenalidomide/dexamethasone, the first immunostimulatory monoclonal antibody for the treatment of relapsed/refractory multiple myeloma. Here, they report 3-year follow-up data.
Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial of Bortezomib Induction and Maintenance in Patients with Newly Diagnosed MM
Researchers report the significant and lasting improvement in progression-free survival and overall survival in patients treated with bortezomib. A subgroup analysis identified bortezomib to have an effect on the high-risk effects of del(17p) and renal impairment on survival.
All-Oral Combination of Ixazomib/Cyclophosphamide/Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed MM
Researchers report the results of a phase 2 study evaluating the tolerability and long-term outcomes using a combination of ixazomib plus cyclophosphamide and low-dose dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not eligible for transplant.
Page 18 of 18
Results 171 - 179 of 179
Results 171 - 179 of 179